The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection

Expert Review of Respiratory Medicine

Volumn 7, Issue 4, 2013, Pages 385-396

  McCaughey, G ^a   Gilpin, D F ^a   Elborn, J S ^a,b   Tunney, Michael M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

anaerobic growth; antibiotic resistance; antibiotics; biofilms; cystic fibrosis; polymicrobial infection; quorum sensing; susceptibility testing

Indexed keywords

AJOENE; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ARIKACE; AZITHROMYCIN; AZTREONAM LYSINE; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; FLUCLOXACILLIN; FOSFOMYCIN; FOSFOMYCIN PLUS TOBRAMYCIN; FUSIDATE SODIUM; GARLIC EXTRACT; IBERIN; LEVOFLOXACIN; NICLOSAMIDE; PSEUDOMONIC ACID; RIFAMPICIN; TEICOPLANIN; TOBRAMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BIOFILM; BURKHOLDERIA CEPACIA; CLINICAL PRACTICE; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; FORCED EXPIRATORY VOLUME; HAEMOPHILUS INFLUENZAE; HUMAN; INFLAMMATION; LIFE EXPECTANCY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATHOGENICITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS; UNSPECIFIED SIDE EFFECT; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BIOFILMS; CHEMISTRY, PHARMACEUTICAL; CYSTIC FIBROSIS; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FORECASTING; HUMANS; MICROBIAL SENSITIVITY TESTS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; QUORUM SENSING; RESPIRATORY TRACT INFECTIONS; TREATMENT FAILURE;

EID: 84887728119     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2013.814411     Document Type: Review

References (117)

1. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur. Respir. J. 29(3), 522-526 (2007).
2. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168(8), 918-951 (2003).
3. Pezzulo AA, Tang XX, Hoegger MJ et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487(7405), 109-113 (2012).
4. Heijerman H. Infection and inflammation in cystic fibrosis: a short review. J. Cyst. Fibros. 4(Suppl. 2), 3-5 (2005).
5. Blackburn L, Brownlee K, Conway S, Denton M. 'Cepacia syndrome' with Burkholderia multivorans, 9 years after initial colonization. J. Cyst. Fibros 3(2), 133-134 (2004).
6. Lambiase A, Catania MR, Del Pezzo M et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 30(8), 973-980 (2011).
7. Waters V, Atenafu EG, Salazar JG et al. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J. Cyst. Fibros. 11(1), 8-13 (2012).
8. Harris JK, De Groote MA, Sagel SD et al. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc. Natl Acad. Sci. USA 104(51), 20529-20533 (2007).
9. Tunney MM, Field TR, Moriarty TF et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 177(9), 995-1001 (2008).
10. Tunney MM, Klem ER, Fodor AA et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 66(7), 579-584 (2011).
11. Fodor AA, Klem ER, Gilpin DF et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS ONE 7(9), e45001 (2012).
12. Sibley CD, Duan K, Fischer C et al. Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections. PLoS Pathog. 4(10), e1000184 (2008).
13. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc. Natl Acad. Sci. USA 105(39), 15070-15075 (2008).
14. Sibley CD, Grinwis ME, Field TR et al. Culture enriched molecular profiling of the cystic fibrosis airway microbiome. PLoS ONE 6(7), e22702 (2011).
15. Parkins MD, Sibley CD, Surette MG, Rabin HR. The Streptococcus milleri group-an unrecognized cause of disease in cystic fibrosis: a case series and literature review. Pediatr. Pulmonol. 43(5), 490-497 (2008).
16. Dore P, Robert R, Grollier G et al. Incidence of anaerobes in ventilator-associated pneumonia with use of a protected specimen brush. Am. J. Respir. Crit. Care Med. 153(4 Pt 1), 1292-1298 (1996).
17. Munck A, Bonacorsi S, Mariani-Kurkdjian P et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr. Pulmonol. 32(4), 288-292 (2001).
18. Folkesson A, Jelsbak L, Yang L et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat. Rev. Microbiol. 10(12), 841-851 (2012).
19. Hansen SK, Rau MH, Johansen HK et al. Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J. 6(1), 31-45 (2012).
20. Aas JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE. Defining the normal bacterial flora of the oral cavity. J. Clin. Microbiol. 43(11), 5721-5732 (2005).
21. Bahrani-Mougeot FK, Paster BJ, Coleman S et al. Molecular analysis of oral and respiratory bacterial species associated with ventilator-associated pneumonia. J. Clin. Microbiol. 45(5), 1588-1593 (2007).
22. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 373(9678), 1891-1904 (2009).
23. Doring G, Flume P, Heijerman H, Elborn JS; Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cyst. Fibros. 11(6), 461-479 (2012).
24. UK CF Trust Infection Control Working Group. Antibiotic Treatment for Cystic Fibrosis. (2009).
25. Flume PA, O'Sullivan BP, Robinson KA et al.; Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 176(10), 957-969 (2007).
26. Smyth A, Walters S. Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. 3, CD001912 (2003).
27. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 23(5), 330-335 (1997).
28. Ratjen F, Munck A, Kho P, Angyalosi G; Group ES. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 65(4), 286-291 (2010).
29. Solis A, Brown D, Hughes J, Van Saene HK, Heaf DP. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatr. Pulmonol. 36(3), 189-195 (2003).
30. Macfarlane M, Leavy A, McCaughan J, Fair R, Reid AJ. Successful decolonization of methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol. J. Hosp. Infect. 65(3), 231-236 (2007).
31. Flume PA, Mogayzel PJ Jr, Robinson KA et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am. J. Respir. Crit. Care Med. 180(9), 802-808 (2009).
32. Waters V, Stanojevic S, Atenafu EG et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur. Resp. J. 40(1), 61-66 (2012).
33. Saiman L. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'. Paediatr. Respir. Rev. 8(3), 249-255 (2007).
34. Saiman L, Anstead M, Mayer-Hamblett N et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 303(17), 1707-1715 (2010).
35. Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. 12, CD002203 (2011).
36. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with cystic fibrosis infected with antibioticresistant Pseudomonas aeruginosa. Respiration. 73(1), 27-33 (2006).
37. Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr. Pulmonol. 45(4), 363-370 (2010).
38. Strateva T, Yordanov D. Pseudomonas aeruginosa-a phenomenon of bacterial resistance. J. Med. Microbiol. 58(Pt 9), 1133-1148 (2009).
39. Smith EE, Buckley DG, Wu Z et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl Acad. Sci. USA 103(22), 8487-8492 (2006).
40. Alcala-Franco B, Montanari S, Cigana C, Bertoni G, Oliver A, Bragonzi A. Antibiotic pressure compensates the biological cost associated with Pseudomonas aeruginosa hypermutable phenotypes in vitro and in a murine model of chronic airways infection. J. Antimicrob. Chemother. 67(4), 962-969 (2012).
41. Oliver A, Canton R, Campo P, Baquero F, Blázquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288(5469), 1251-1254 (2000).
42. Ciofu O, Riis B, Pressler T, Poulsen HE, Hoiby N. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob. Agents Chemother. 49(6), 2276-2282 (2005).
43. Ferroni A, Guillemot D, Moumile K et al. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis. Pediatr. Pulmonol. 44(8), 820-825 (2009).
44. Hoffman LR, Deziel E, D'Argenio DA et al. Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc. Natl Acad. Sci. USA 103(52), 19890-19895 (2006).
45. Nakaminami H, Noguchi N, Sasatsu M. Fluoroquinolone efflux by the plasmidmediated multidrug efflux pump QacB variant QacBIII in Staphylococcus aureus. Antimicrob. Agents Chemother. 54(10), 4107-4111 (2010).
46. Hackbarth CJ, Chambers HF. blaI and blaR1 regulate beta-lactamase and PBP 2a production in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 37(5), 1144-1149 (1993).
47. Hafer C, Lin Y, Kornblum J, Lowy FD, Uhlemann AC. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 56(11), 5845-5851 (2012).
48. Mahenthiralingam E, Urban TA, Goldberg JB. The multifarious, multireplicon Burkholderia cepacia complex. Nat. Rev. Microbiol 3(2), 144-156 (2005).
49. Nzula S, Vandamme P, Govan JRW. Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. J. Antimicrob. Chemother. 50(2), 265-269 (2002).
50. Bador J, Amoureux L, Duez J-M et al. First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM. Antimicrob. Agents Chemother. 55(10), 4912-4914 (2011).
51. Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin. Infect. Dis. 32( Suppl. 2), S104-S113 (2001).
52. Milne KEN, Gould IM. Combination antimicrobial susceptibility testing of multidrug-resistant Stenotrophomonas maltophilia from cystic fibrosis patients. Antimicrob. Agents Chemother. 56(8), 4071-4077 (2012).
53. Grinwis ME, Sibley CD, Parkins MD, Eshaghurshan CS, Rabin HR, Surette MG. Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. Antimicrob. Agents Chemother. 54(7), 2823-2829 (2010).
54. Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin. Microbiol. Rev. 15(4), 716-746 (2002).
55. Madinier I, Fosse T, Giudicelli J, Labia R. Cloning and biochemical characterization of a class A beta-lactamase from Prevotella intermedia. Antimicrob. Agents Chemother. 45(8), 2386-2389 (2001).
56. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407(6805), 762-764 (2000).
57. Costerton JW. Introduction to biofilm. Int. J. Antimicrob. Agents 11(3-4), 217-221; discussion 237-219 (1999).
58. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J. Clin. Microbiol. 42(5), 1915-1922 (2004).
59. Hoiby N. Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies. J. Cyst. Fibros. 1(4), 249-254 (2002).
60. Harrison JJ, Turner RJ, Ceri H. Persister cells, the biofilm matrix and tolerance to metal cations in biofilm and planktonic Pseudomonas aeruginosa. Environ. Microbiol. 7(7), 981-994 (2005).
61. Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms. Int. J. Med. Microbiol. 292(2), 107-113 (2002).
62. Schobert M, Jahn D. Anaerobic physiology of Pseudomonas aeruginosa in the cystic fibrosis lung. Int. J. Med. Microbiol. 300(8), 549-556 (2010).
63. Palmer KL, Brown SA, Whiteley M. Membrane-bound nitrate reductase is required for anaerobic growth in cystic fibrosis sputum. J. Bacteriol. 189(12), 4449-4455 (2007).
64. Yoon SS, Hennigan RF, Hilliard GM et al. Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev. Cell 3(4), 593-603 (2002).
65. Hassett DJ. Anaerobic production of alginate by Pseudomonas aeruginosa: alginate restricts diffusion of oxygen. J. Bacteriol. 178(24), 7322-7325 (1996).
66. King JD, Kocincova D, Westman EL, Lam JS. Review: Lipopolysaccharide biosynthesis in Pseudomonas aeruginosa. Innate Immun. 15(5), 261-312 (2009).
67. Hentzer M, Teitzel GM, Balzer GJ et al. Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J. Bacteriol. 183(18), 5395-5401 (2001).
68. Kadurugamuwa JL, Lam JS, Beveridge TJ. Interaction of gentamicin with the A band and B band lipopolysaccharides of Pseudomonas aeruginosa and its possible lethal effect. Antimicrob. Agents Chemother. 37(4), 715-721 (1993).
69. Field TR, White A, Elborn JS, Tunney MM. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms. Eur. J. Clin. Microbiol. Infect. Dis. 24(10), 677-687 (2005).
70. King P, Citron DM, Griffith DC, Lomovskaya O, Dudley MN. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients. Diagn. Microbiol. Infect. Dis. 66(2), 181-186 (2010).
71. McCaughey G, McKevitt M, Elborn JS, Tunney MM. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. J. Cyst. Fibros. 11(3), 163-172 (2012).
72. Schaible B, Taylor CT, Schaffer K. Hypoxia increases antibiotic resistance in Pseudomonas aeruginosa through altering the composition of multidrug efflux pumps. Antimicrob. Agents Chemother. 56(4), 2114-2118 (2012).
73. Hurley MN, Ariff AH, Bertenshaw C, Bhatt J, Smyth AR. Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J. Cyst. Fibros. 11(4), 288-292 (2012).
74. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 123(5), 1495-1502 (2003).
75. Parkins MD, Rendall JC, Elborn JS. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 141(2), 485-493 (2012).
76. Aaron SD, Vandemheen KL, Ferris W et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366(9484), 463-471 (2005).
77. Lang BJ, Aaron SD, Ferris W, Hebert PC, MacDonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 162(6), 2241-2245 (2000).
78. Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JL. Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J. Antimicrob. Chemother. 56(5), 879-886 (2005).
79. Moskowitz SM, Emerson JC, McNamara S et al. Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr. Pulmonol. 46(2), 184-192 (2011).
80. Keays T, Ferris W, Vandemheen KL et al. A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations. J. Cyst. Fibros. 8(2), 122-127 (2009).
81. Foweraker JE, Laughton CR, Brown DF, Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J. Antimicrob. Chemother. 55(6), 921-927 (2005).
82. Bals R, Hubert D, Tummler B. Antibiotic treatment of CF lung disease: from bench to bedside. J. Cyst. Fibros. 10(Suppl. 2), S146-S151 (2011).
83. Retsch-Bogart GZ, Quittner AL, Gibson RL et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 135(5), 1223-1232 (2009).
84. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178(9), 921-928 (2008).
85. Oermann CM, Retsch-Bogart GZ, Quittner AL et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr. Pulmonol. 45(11), 1121-1134 (2010).
86. Wainwright CE, Quittner AL, Geller DE et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J. Cyst. Fibros. 10(4), 234-242 (2011).
87. Assael BM, Pressler T, Bilton D et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial. J. Cyst. Fibros. 12(2), 130-140 (2012).
88. Konstan MW, Flume PA, Kappler M et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J. Cyst. Fibros. 10(1), 54-61 (2011).
89. Konstan MW, Geller DE, Minić P, Brockhaus F, Zhang J, Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatr. Pulmonol. 46(3), 230-238 (2011).
90. Minic P, Fustik S, Solyom E et al. A multi-cycle open-label study of nebulized liposomal amikacin (Arikace™) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. Pediatr. Pulmonol. (Suppl 33), 243 (2010).
91. Clancy J, Minic P, Dupont L et al. Full analyses of data from two Phase II blinded and placebo-controlled studies of nebulized liposomal amikacin for inhalation (Arikace™) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. Pediatr. Pulmonol. (Suppl. 33), 227(2010).
92. Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 183(11), 1510-1516 (2011).
93. Wilson R, Welte T, Polverino E et al. Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomised study. Eur. Respir. J. doi:10.1183/09031936.00071312 (2013).
94. MacLeod DL, Barker LM, Sutherland JL et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J. Antimicrob. Chemother. 64(4), 829-836 (2009).
95. Trapnell BC, McColley SA, Kissner DG et al. Fosfomycin/tobramycin for inhalation in cystic fibrosis patients with pseudomonas airway infection. Am. J. Respir. Crit. Care Med. 185(2), 171-178 (2012).
96. Geller DE, Flume PA, Griffith DC et al. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob. Agents Chemother. 55(6), 2636-2640 (2011).
97. Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473(7346), 216-220 (2011).
98. Howlin R, Cathie K, Hall-Stoodley L et al. Nitric oxide-mediated dispersal and enhanced antibiotic sensitivity in Pseudomonas aeruginosa biofilms from the cystic fibrosis lung. Arch. Dis. Child 96(Suppl. 1), A45 (2011).
99. Sommerfeld Ross S, Fiegel J. Nutrient dispersion enhances conventional antibiotic activity against Pseudomonas aeruginosa biofilms. Int. J. Antimicrob. Agents 40(2), 177-181 (2012).
100. Rogers SA, Huigens RW 3rd, Cavanagh J, Melander C. Synergistic effects between conventional antibiotics and 2-aminoimidazole-derived antibiofilm agents. Antimicrob. Agents Chemother. 54(5), 2112-2118 (2010).
101. Miller MB, Bassler BL. Quorum sensing in bacteria. Annu. Rev. Microbiol. 55, 165-199 (2001).
102. Tateda K, Comte R, Pechere JC, Kohler T, Yamaguchi K, Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 45(6), 1930-1933 (2001).
103. Wu H, Song Z, Hentzer M et al. Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J. Antimicrob. Chemother. 53(6), 1054-1061 (2004).
104. Galloway WR, Hodgkinson JT, Bowden S, Welch M, Spring DR. Applications of small molecule activators and inhibitors of quorum sensing in Gram-negative bacteria. Trends Microbiol. 20(9), 449-458 (2012).
105. Bjarnsholt T, Jensen PO, Rasmussen TB et al. Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology 151(Pt 12), 3873-3880 (2005).
106. Smyth AR, Cifelli PM, Ortori CA et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis-a pilot randomized controlled trial. Pediatr. Pulmonol. 45(4), 356-362 (2010).
107. Jakobsen TH, van Gennip M, Phipps RK et al. Ajoene, a sulfur-rich molecule from garlic, inhibits genes controlled by quorum sensing. Antimicrob. Agents Chemother. 56(5), 2314-2325 (2012).
108. Jakobsen TH, Bragason SK, Phipps RK et al. Food as a source for quorum sensing inhibitors: iberin from horseradish revealed as a quorum sensing inhibitor of Pseudomonas aeruginosa. Appl. Environ. Microbiol. 78(7), 2410-2421 (2012).
109. Christensen LD, van Gennip M, Jakobsen TH et al. Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model. J. Antimicrob. Chemother. 67(5), 1198-1206 (2012).
110. Skindersoe ME, Alhede M, Phipps R et al. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52(10), 3648-3663 (2008).
111. Imperi F, Massai F, Ramachandran Pillai C et al. New life for an old drug: the anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum sensing. Antimicrob. Agents Chemother. 57(2), 996-1005 (2013).
112. Kohler T, Perron GG, Buckling A, van Delden C. Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa. PLoS Pathog. 6(5), e1000883 (2010).
113. Moore JE, Crowe M, Shaw A, McCaughan J, Redmond AO, Elborn JS. Antibiotic resistance in Burkholderia cepacia at two regional cystic fibrosis centres in Northern Ireland: is there a need for synergy testing? J. Antimicrob. Chemother. 48(2), 319-321 (2001).
114. Koser CU, Holden MT, Ellington MJ et al. Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak. N. Engl. J. Med. 366(24), 2267-2275 (2012).
115. Berkhout MC, Rijntjes E, El Bouazzaoui LH, Fokkens WJ, Brimicombe RW, Heijerman HG. Importance of bacteriology in upper airways of patients with cystic fibrosis J. Cyst. Fibros. (2013).
116. Mainz JG, Michl R, Pfister W, Beck JF. Cystic fibrosis upper airways primary colonization with Pseudomonas aeruginosa: eradicated by sinonasal antibiotic inhalation. Am. J. Respir. Crit. Care Med. 184(9), 1089-1090 (2011).
117. Kirby T. Europe to boost development of new antimicrobial drugs. Lancet 379(9833), 2229-2230 (2012).